BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• Business

  LimmaTech Appoints Staph Leavenworth Bakali as Chairman of the Board

  LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors.

  July 1, 2024

   · 

  3 min read
• Pharm Country

  BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on Monday, July 8, at 8:00 a.m. U.S. Eastern Time.

  July 1, 2024

   · 

  4 min read
• Press Releases

  Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024

  Avid Bioservices, Inc. today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).

  July 1, 2024

   · 

  1 min read
• Press Releases

  Q32 Bio Joins Russell 3000® Index

  Q32 Bio Inc. today announced that the company is joining the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.

  July 1, 2024

   · 

  6 min read
• Press Releases

  OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

  OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

  July 1, 2024

   · 

  9 min read
• Press Releases

  Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA

  Nyxoah announced that the Company submitted the fourth and final module of its Premarket Approval application for Genio to the U.S. Food and Drug Administration (FDA).

  July 1, 2024

   · 

  5 min read
• Policy

  FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara

  Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration has approved the Biologics License Application for PYZCHIVA® subcutaneous injection and intravenous infusion as a biosimilar to Stelara.

  July 1, 2024

   · 

  10 min read
• Policy

  TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease

  TauRx Pharmaceuticals Ltd has announced the submission of a UK Marketing Authorisation Application for hydromethylthionine mesylate for treatment of mild cognitive impairment and mild to moderate stages of dementia due to Alzheimer’s disease.

  July 1, 2024

   · 

  3 min read
• KFSHRC Performs Over 5,000 Successful Kidney Transplants

  King Faisal Specialist Hospital and Research Centre has successfully performed 5,000 kidney transplants since the inception of its Transplant Program in 1981, placing it among a select group of leading global health centres that have achieved this milestone.

  July 1, 2024

   · 

  2 min read
• Business

  Fennec Pharmaceuticals Announces Management Change

  Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.

  July 1, 2024

   · 

  4 min read